NEO
Neogenomics Inc.

2,854
Mkt Cap
$1.56B
Volume
382,395.00
52W High
$14.73
52W Low
$4.72
PE Ratio
-13.59
NEO Fundamentals
Price
$12.28
Prev Close
$12.06
Open
$12.17
50D MA
$12.14
Beta
1.43
Avg. Volume
1.6M
EPS (Annual)
-$0.6216
P/B
1.85
Rev/Employee
$300,257.27
Loading...
Loading...
News
all
press releases
165,890 Shares in NeoGenomics, Inc. $NEO Purchased by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Analysts
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has received a consensus recommendation of "Hold" from the thirteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One...
MarketBeat·5d ago
News Placeholder
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025...
Business Wire·6d ago
News Placeholder
NeoGenomics (NASDAQ:NEO) COO Sells $276,600.00 in Stock
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) COO Warren Stone sold 22,128 shares of the company's stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of...
MarketBeat·11d ago
News Placeholder
NeoGenomics (NASDAQ:NEO) COO Sells 22,128 Shares of Stock
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) COO Warren Stone sold 22,128 shares of the business's stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average...
MarketBeat·12d ago
News Placeholder
NeoGenomics (NASDAQ:NEO) Shares Down 7.4% - Here's What Happened
NeoGenomics (NASDAQ:NEO) Stock Price Down 7.4% - What's Next...
MarketBeat·21d ago
News Placeholder
NeoGenomics (NASDAQ:NEO) Earns "Buy" Rating from Needham & Company LLC
Needham & Company LLC reaffirmed a "buy" rating and set a $14.00 target price on shares of NeoGenomics in a report on Monday...
MarketBeat·21d ago
News Placeholder
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced preliminary fourth quarter and full-year 2025 revenue and also...
Business Wire·21d ago
News Placeholder
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the upcoming 44th Annual J.P...
Business Wire·28d ago
News Placeholder
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of "Hold" by Analysts
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has been given a consensus rating of "Hold" by the fifteen analysts that are currently covering the company, Marketbeat reports. One investment...
MarketBeat·29d ago
<
1
2
...
>

Latest NEO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.